07:16 AM EST, 01/08/2025 (MT Newswires) -- Maze Therapeutics on Tuesday filed for a US initial public offering. Terms of the IPO were not disclosed in the filing.

The company said it will use the funds raised from the offering along with existing cash to advance the clinical development of its lead programs, MZE829 and MZE782, for other discovery and preclinical programs, working capital and other general corporate purposes.

Maze plans to list its shares on the Nasdaq Global Market under the ticker symbol "MAZE".